Intrinsiqq
Century Therapeutics, Inc. logo

Century Therapeutics, Inc.

IPSC

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$250M
EPS-$0.64
P/E-2.15
P/FCF-2.94
EV/EBITDA-1.60
FCF Yield–
Div. Yield–
Net Debt/FCF0.9x
Century Therapeutics, Inc. intrinsic value
52-Week Range
$0.48$2.94

Profitability & Returns

Revenue (FY)

$109M

▲ +1556.8% YoY

Net Income (TTM)

-$99M

▲ +92.4% YoY

Op. Margin

-15.82%

▲ +2080.7pp YoY

ROIC

-32.43%

▲ +42.2pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$85M

▲ +5.0% YoY

Op. Cash Flow (TTM)

-$83M

▲ +5.7% YoY

Net Debt

-$80M

Net Cash Position

Cash & Equiv.

$117M

3Y CAGR: +175.9%

Continue Research

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with IPSC

CompareIntrinsic value
KYMRKymera Therapeutics Inc.
$125.85-1.35%25
FDMT4D Molecular Therapeutics, Inc.
$10.79-4.43%40
DNAGinkgo Bioworks Holdings Inc.
$8.50-11.55%15
PLXProtalix Biotherapeutics Inc.
$3.03-0.66%88
AGENAgenus Inc.
$6.29-6.54%56
AUTLAutolus Therapeutics plc
$1.14-2.56%40
CGENCompugen Ltd.
$2.04-2.86%75
BEAMBeam Therapeutics Inc.
$20.65-1.38%40

Held by ETFs

IPSC is in 2 US ETFs. The largest of them, with IPSC's weight in each:

Century Therapeutics (IPSC) in four numbers

Fair value (revenue)
$6.51
Price $1.38 is 79% below it.
Intrinsic Value
Quality score
40/100
Best check: revenue growth, 175.9%. Weakest: return on capital, -32.4%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-2.15
Negative: a loss over the last twelve months. Price to free cash flow -2.94.
Financials

Questions about Century Therapeutics

Is Century Therapeutics (IPSC) overvalued?

At $1.38, Century Therapeutics' price is 79% below the $6.51 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

What is Century Therapeutics' fair value?

Intrinsiqq's calculator puts Century Therapeutics' fair value at $6.51 a share. It grows revenue per share 30% a year for 5 years, applies an exit P/S of 4.7, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $4.89. Every input can be changed on the Intrinsic Value tab.

Is Century Therapeutics a high-quality business?

Century Therapeutics scores 40 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 6 checks computed from SEC filings. Its best check is revenue growth at 175.9%, and its weakest is return on capital at -32.4%. The Quality tab shows every check against its target.

Does Century Therapeutics (IPSC) pay a dividend?

No. Century Therapeutics (IPSC) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 5 Nov 2026 (period ending 30 Sept 2026), SEC. Price: live 17 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in IPSC's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing IPSC

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.